Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (NYSE: ABT) received CE Mark for Libre Duo and Libre Duo 10 Day, the world's first dual continuous glucose‑ketone sensing systems for people with diabetes. The sensors measure both biomarkers every minute, support daily glucose management, and may help detect rising ketones linked to diabetic ketoacidosis (DKA).
Libre Duo offers up to 15 days of wear for adults; Libre Duo 10 Day provides up to 10 days for users aged 2 and older. Both integrate with Abbott's Libre digital ecosystem and are designed for compatibility with automated insulin delivery systems. Libre Duo is not yet cleared or available in the United States; launches in select European countries are planned later in 2026.
Abbott (NYSE:ABT) announced that updated American Cancer Society colorectal cancer screening guidelines reaffirm Cologuard and Cologuard Plus as preferred noninvasive options for average‑risk adults 45+ on a three‑year interval.
Abbott highlights strong test performance, real‑world adherence, and plans to commercialize a complementary blood‑based test pending FDA approval.
Abbott (NYSE:ABT) will showcase 11 cancer diagnostics abstracts at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2, 2026. Presentations span multi-cancer early detection, molecular residual disease, breast recurrence risk, colorectal screening and pipeline innovation.
Highlights include new MRD data from the PARTNER trial in early triple-negative breast cancer, early real-world data on the Cancerguard multi-cancer early detection blood test, AI-driven risk stratification using the Oncotype DX Breast Recurrence Score, a vaginal-swab-based endometrial cancer test, and updated analyses for the Cologuard colorectal cancer screening test.
Abbott (NYSE: ABT) received FDA clearance and a CE Mark for Ultreon 3.0, its next-generation AI-powered coronary imaging platform, on April 28, 2026. Ultreon 3.0 combines high-resolution OCT imaging, a one-second OCT pullback, and AI-automated insights to support planning, stent sizing, and post-procedure assessment for complex PCI.
The platform aims to speed workflows, reduce contrast use (relevant for ~25% of CAD patients with kidney disease), and provide real-time guidance to clinicians treating complex coronary artery disease.
Abbott (NYSE: ABT) presented four late-breaking clinical datasets at Heart Rhythm Society 2026 showing positive outcomes for pulsed field ablation (PFA) and conduction system pacing (CSP) technologies.
Key six-month and early follow-up results: TactiFlex Duo showed 87% arrhythmia-free and 98.3% safety in 188 patients; Volt PFA reported efficient treatment (4.1 applications per vein; 10.7 per PWI) with no procedure-related complications; CSP leads (UltiSynq and AVEIR) showed high implantation success, strong safety metrics, and stable early electrical performance.
Abbott (NYSE: ABT) reported AACR 2026 data showing its Cancerguard multi-cancer early detection test uses a multi-biomarker methylation-plus-protein approach to improve detection across stages. In a case-control study, signals were 47.1% methylation-only, 7.4% protein-only, 45.5% combined; false positives were 2.6% and none were positive for both markers. The AACR award noted DETECT-A multiyear outcomes with ~4-year median follow-up, where treated stage I–II patients remained alive and cancer-free.
Abbott (NYSE: ABT) reported 1Q26 sales of $11,164 million (reported) and comparable sales growth of 3.7%. GAAP diluted EPS was $0.61; adjusted diluted EPS was $1.15. Abbott completed the acquisition of Exact Sciences on March 23, 2026.
Full-year 2026 guidance: comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58, which includes $0.20 dilution from Exact Sciences. Quarterly dividend of $0.63 payable May 15, 2026.
Abbott (NYSE: ABT) released a national survey (April 9, 2026) finding 74% of U.S. adults believe most chronic diseases are preventable, yet only 1 in 4 feel very confident managing their health.
The survey of 4,000 U.S. adults highlights confusion from conflicting guidance, cost barriers, generational differences, and Abbott's partnership with Sesame Workshop to provide free healthy-habit resources.
Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026. The integration lets clinicians order Abbott tests and receive results inside the OncoEMR workflow, expanding access across Flatiron's network of 1,600+ community cancer centers and 4,700 providers.
This single, unified experience covers Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to reduce administrative burden and accelerate informed treatment decisions in community oncology settings.
Abbott (NYSE: ABT) will report first-quarter 2026 financial results on Thursday, April 16, 2026, before the market opens. The results will be followed by a live earnings conference call and webcast at 8:00 a.m. Central / 9:00 a.m. Eastern.
According to the company, the webcast will be accessible via Abbott's investor relations website and an archived edition will be available later that day.